Day: March 23, 2020

AttachmentSCANFIL_23.3_trades

Eimskip‘s Annual General Meeting will be held Thursday 26 March on 16:00 GMT.The Icelandic government has enforced stricter measures in Iceland to halt the spread of Covid-19 infections, following a swift diagnosis of such cases. The measures are based on recommendations from the Chief Epidemiologist to Iceland’s Minister of Health, i.a. a ban on gatherings of 20 people or more. Eimskip is an important company in its core market in the North Atlantic and must at these unprecedented times secure and maintain its logistics chain and good consumer service. As a result the Board of Directors asks shareholders not to attend the Annual General Meeting, but rather cast their votes in a written manner before the meeting starts and to grant the chairman of the meeting a power of attorney to vote on their behalf in the meeting.Written voting prior...

Aðalfundur Eimskipafélags Íslands hf. verður haldinn fimmtudaginn 26. mars kl. 16:00.Heilbrigðisráðherra hefur ákveðið, í samræmi við tillögu sóttvarnarlæknis, að takmarka samkomur enn frekar en áður vegna hraðari útbreiðslu Covid-19 í samfélaginu. Fundir þar sem fleiri en 20 manns koma saman eru bannaðir. Eimskip er mikilvægt fyrirtæki i flutningaþjónustu og þarf á þessum fordæmalausum tímum að tryggja virkni flutningakeðjunnar og þjónustu við viðskiptavini og landsmenn alla. Vegna þessa biður stjórn félagsins hluthafa um að mæta ekki á fundinn heldur kjósa fyrirfram og skriflega um tillögur fundarins og veita fundarstjóra umboð til að kjósa á fundinum fyrir sína hönd.Skrifleg fyrirfram kosningAtkvæðaseðill með umboði er hjálagt og aðgengilegur á heimasíðu félagsins:https://www.eimskip.com/investors/shareholder-meetings/annual-general-meeting-2020/Frestur...

LiiteINVEST_23.3_trades

23.03.2020 at 18:30UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 23.03.2020The shares held by United Bankers Corporation on 23.03.2020:On behalf of United Bankers CorporationAntti Salakka         Mikko VirtanenFor more information, please contact:Patrick Anderson, toimitusjohtaja, United Bankers OyjSähköposti: patrick.anderson@unitedbankers.fiPuhelin: 0400 244 544,09 25 380 236www.unitedbankers.fiAttachmentUB SBB 23032020

 23.03.2020 klo 18:30 UNITED BANKERS OYJ:n OMIEN OSAKKEIDEN HANKINTA 23.03.2020Yhtiön hallussa olevat omat osakkeet 23.03.2020:  United Bankers Oyj:n puolesta  Antti Salakka         Mikko Virtanen Lisätietoja antaa:Patrick Anderson, toimitusjohtaja, United Bankers OyjSähköposti: patrick.anderson@unitedbankers.fiPuhelin: 0400 244 544,09 25 380 236www.unitedbankers.fiLiiteUB SBB 23032020

阿爾伯塔省卡加利, March 24, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp.（以下簡稱「 Resverlogix」）（TSX：RVX）宣佈正為臨床前或臨床模型，尋求與目前正在測試 SARS-CoV-2療法(對新冠狀病毒作出反應的病毒）的組織合作。Apabetalone 可以防止被稱為溴結構域和末端外域（BET）的特殊蛋白激活疾病相關基因和其他基因的傳遞、可以破壞 SARS-CoV-2 的繁殖，同時也限制病毒進入人類細胞。最近 在 2020 年 3 月 17 日於《紐約時報》上發表的最新文章表示: 加利福尼亞大學舊金山分校定量生物科學研究所冠狀病毒研究小組的研究人員確定了人類含溴域蛋白（BRD2） – apabetalone 的直接目標 – 是SARS-CoV-2 的關鍵互動夥伴。出版刊物待定。BRD2 與病毒顆粒的 E（包膜）蛋白結合，並被認定為參與了病毒的繁殖過程。此外，已知 apabetalone 單獨抑制 血管收縮素轉換酶2（ACE2） 的傳遞，這些受體是新冠狀病毒顆粒用於進入人體細胞的受體 。總括而言，這些觀察結果表明了 apabetalone 治療可能會減少病毒進入細胞的速度，並限制病毒顆粒的複制能力。「Resverlogix 準備立即採取行動，以幫助全球解決新冠肺炎的大流行，而目前尚未有有效的治療方法。我們必須迅速採取行動！」Resverlogix 的主席兼行政總裁 Donald McCaffrey 說。「如三期臨床試驗的結果所顯示，Apabetalone 是唯一具有臨床安全記錄的 BET 抑製劑， BETonMACE。該類別中沒有其他療法可以直接進入後期臨床試驗，我們期望迅速與任何在臨床前和臨床研究中測試新冠肺炎藥物的人士合作。為幫助加快在這領域的發展，我們鼓勵患者權益團體、政府衛生機構、製藥公司和／或非政府研究組織等感興趣的利益相關者聯絡 Resverlogix，以助進一步研究和開發 apabetalone...

阿尔伯塔省卡尔加里, March 24, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp.（以下简称“Resverlogix”）（TSX：RVX）宣布，公司正在寻求目前测试新冠病毒（SARS-CoV-2）临床前或临床模型的组织进行合作。Apabetalone可以防止称为溴区结构域（BET）和超末端蛋白的特殊蛋白激活与疾病相关和其他基因的表现，从而可以破坏新冠病毒的繁殖，同时也可以限制病毒进入人体细胞。在《纽约时报》2020年3月17日出版的一篇文章中报道，位于加利福尼亚大学旧金山分校的定量生物科学研究所冠状病毒研究小组的研究人员将Apabetalone的直接靶标——人溴结构域蛋白（BRD2），确定为新冠病毒的关键相互作用蛋白。 该文章正待发表。BRD2与病毒颗粒的E（包膜）蛋白结合，并被认为参与了病毒的繁殖过程。此外，Apabetalone已知可用来抑制血管紧张素转化酶2（ACE2）的表达，这是新型冠状病毒颗粒用于进入人体细胞的受体。总之，这些观察结果表明，Apabetalone的治疗可能会减少病毒进入细胞并限制病毒颗粒的复制能力。“Resverlogix准备立即采取行动，以帮助解决目前尚无有效治疗方法的新冠肺炎的全球大流行。我们必须迅速采取行动，” Resverlogix总裁兼首席执行官Donald McCaffrey表示。“正如第3期试验BETonMACE的结果所显示，Apabetalone是唯一具有可靠临床安全记录的BET抑制剂。该类别中没有其他疗法可以直接进入后期临床试验，我们希望与临床前和临床研究中测试新冠病毒药物的任何组织迅速展开合作。为帮助加快该领域的发展，我们鼓励患者权益团体、政府卫生机构、制药公司和/或非政府研究组织等感兴趣的利益相关者联系Resverlogix，以进一步研究和开发Apabetalone作为新冠病毒的治疗方法。对新冠有兴趣的合作单位可以通过以下方式联系：Donald McCaffrey，总裁兼首席执行官don@resverlogix.com1-587-390-7888关于ResverlogixResverlogix目前正在开发Apabetalone（RVX-208），这种新型小分子药物是一种选择性BET（溴结构域和超末端结构域）抑制剂。BET抑制是一种表观遗传机制，可调控致病基因。Apabetalone是一种选择性BET抑制剂，适用于BET蛋白质内的第二溴结构域（BD2）...

Danske Bank A/S supports initiatives to mitigate the financial consequences of COVID-19, including reassessing proposal for payment of dividendsThe COVID-19 pandemic poses a serious threat to the economy. As one of the largest banks in the Nordic countries and the largest bank in Denmark, we play an important role in contributing to minimise the negative economic consequences for our customers and society as a whole.For this reason, on 15 March 2020, we announced a series of measures aimed at offering extended help and flexibility for individuals and businesses who are impacted financially by this extraordinary situation.These initiatives include expanded access to overdrafts, payment in instalments, increases of facilities and extension of terms. We also suspended the charging of negative interest rates for the rest of the year for up...

(Oslo, Norway, 23 March 2020) StrongPoint ASA (StrongPoint, OSE: STRONG) today provides a business update for the COVID-19 implications on the company’s operations. StrongPoint experiences a strong and accelerated interest for its e-commerce solutions, but sees a negative effect on non-grocery offerings due to the governmental restrictions on travelling and social distancing. StrongPoint has a solid financial position and reiterates the long-term outlook.“In our work to manage the COVID-19 situation we keep the well-being of our employees, customers and business partners as our priority number one. Both to secure our day-to-day operations, and to contribute to the pan-national efforts to protect vulnerable groups. We are monitoring the situation 24/7 and follow current provisions, restrictions and recommendations closely. StrongPoint...